Georgia Retina Participates in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy

ATLANTA--(BUSINESS WIRE)--Georgia Retina is proud to be among the first eyecare practices throughout the country to utilize and participate in Apellis Pharmaceuticals’ groundbreaking clinical trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy (GA). GA is a leading cause of blindness that impacts more than one million people in the U.S. and five million people worldwide (source 1,2). Georgia Retina has a long history of commitment to and participation in clinica